Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients

Rita Murri, Marta Camici, Brunella Posteraro, Francesca Giovannenze, Francesco Taccari, Giulio Ventura, Giancarlo Scoppettuolo, Maurizio Sanguinetti, Roberto Cauda, Massimo Fantoni

Research output: Contribution to journalArticle

Abstract

Objectives: To assess the performance of the (1,3)-β-D-glucan (BDG) detection assay in a large cohort of patients with suspected candidemia who were admitted to non-intensive care unit hospital wards.

Methods: This observational, retrospective cohort study was conducted in a 1,100-bed university hospital in Rome, where an infectious disease consultation team has been operational. Two groups of patients were included in the analysis: Group 1, patients with Candida bloodstream infection (BSI) who had at least one BDG test performed ±48 hours from the first positive blood culture (Candida BSI Group) and Group 2, patients with risk factors for candidemia who had at least one BDG test but had negative blood cultures (Control Group). Both Group 1 and Group 2 did not receive prior antifungal therapy. Different BDG cutoff values were considered: 80, 200, 300, 400, and ≥500 pg/mL. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve were calculated.

Results: A total of 1,296 patients were studied. Of them, 100 patients (candidemic) were in Group 1 and the remaining 1,196 patients (controls) were in Group 2. There were no differences in demographic characteristics between patients of the two groups. According to the above cutoff values, sensitivity (%) and specificity (%) of the BDG assay ranged from 91 to 60.7 and 87.7 to 97.8, respectively, whereas the PPV (%) and NPV (%) ranged from 38.2 to 68.3 and 99.1 to 97.0, respectively.

Conclusion: Serum BDG has a very high NPV in a population witĥ10% prevalence of candidemia. This NPV may support decisions to discontinue antifungal therapy in those patients who were empirically treated because of the suspect of candidemia.

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalInfection and Drug Resistance
Volume12
DOIs
Publication statusPublished - 2019

Fingerprint

Candidemia
Candida
polyglucosan
Sensitivity and Specificity
Hospital Units
Infection
ROC Curve
Communicable Diseases
Cohort Studies
Referral and Consultation
Retrospective Studies
Demography
Control Groups
Therapeutics
Serum
Population
Blood Culture

Cite this

Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients. / Murri, Rita; Camici, Marta; Posteraro, Brunella; Giovannenze, Francesca; Taccari, Francesco; Ventura, Giulio; Scoppettuolo, Giancarlo; Sanguinetti, Maurizio; Cauda, Roberto; Fantoni, Massimo.

In: Infection and Drug Resistance, Vol. 12, 2019, p. 19-24.

Research output: Contribution to journalArticle

Murri, Rita ; Camici, Marta ; Posteraro, Brunella ; Giovannenze, Francesca ; Taccari, Francesco ; Ventura, Giulio ; Scoppettuolo, Giancarlo ; Sanguinetti, Maurizio ; Cauda, Roberto ; Fantoni, Massimo. / Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients. In: Infection and Drug Resistance. 2019 ; Vol. 12. pp. 19-24.
@article{2aa922d31d83405cba8c5ccc8da60cfe,
title = "Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients",
abstract = "Objectives: To assess the performance of the (1,3)-β-D-glucan (BDG) detection assay in a large cohort of patients with suspected candidemia who were admitted to non-intensive care unit hospital wards.Methods: This observational, retrospective cohort study was conducted in a 1,100-bed university hospital in Rome, where an infectious disease consultation team has been operational. Two groups of patients were included in the analysis: Group 1, patients with Candida bloodstream infection (BSI) who had at least one BDG test performed ±48 hours from the first positive blood culture (Candida BSI Group) and Group 2, patients with risk factors for candidemia who had at least one BDG test but had negative blood cultures (Control Group). Both Group 1 and Group 2 did not receive prior antifungal therapy. Different BDG cutoff values were considered: 80, 200, 300, 400, and ≥500 pg/mL. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve were calculated.Results: A total of 1,296 patients were studied. Of them, 100 patients (candidemic) were in Group 1 and the remaining 1,196 patients (controls) were in Group 2. There were no differences in demographic characteristics between patients of the two groups. According to the above cutoff values, sensitivity ({\%}) and specificity ({\%}) of the BDG assay ranged from 91 to 60.7 and 87.7 to 97.8, respectively, whereas the PPV ({\%}) and NPV ({\%}) ranged from 38.2 to 68.3 and 99.1 to 97.0, respectively.Conclusion: Serum BDG has a very high NPV in a population witĥ10{\%} prevalence of candidemia. This NPV may support decisions to discontinue antifungal therapy in those patients who were empirically treated because of the suspect of candidemia.",
author = "Rita Murri and Marta Camici and Brunella Posteraro and Francesca Giovannenze and Francesco Taccari and Giulio Ventura and Giancarlo Scoppettuolo and Maurizio Sanguinetti and Roberto Cauda and Massimo Fantoni",
year = "2019",
doi = "10.2147/IDR.S181489",
language = "English",
volume = "12",
pages = "19--24",
journal = "Infection and Drug Resistance",
issn = "1178-6973",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Performance evaluation of the (1,3)-β-D-glucan detection assay in non-intensive care unit adult patients

AU - Murri, Rita

AU - Camici, Marta

AU - Posteraro, Brunella

AU - Giovannenze, Francesca

AU - Taccari, Francesco

AU - Ventura, Giulio

AU - Scoppettuolo, Giancarlo

AU - Sanguinetti, Maurizio

AU - Cauda, Roberto

AU - Fantoni, Massimo

PY - 2019

Y1 - 2019

N2 - Objectives: To assess the performance of the (1,3)-β-D-glucan (BDG) detection assay in a large cohort of patients with suspected candidemia who were admitted to non-intensive care unit hospital wards.Methods: This observational, retrospective cohort study was conducted in a 1,100-bed university hospital in Rome, where an infectious disease consultation team has been operational. Two groups of patients were included in the analysis: Group 1, patients with Candida bloodstream infection (BSI) who had at least one BDG test performed ±48 hours from the first positive blood culture (Candida BSI Group) and Group 2, patients with risk factors for candidemia who had at least one BDG test but had negative blood cultures (Control Group). Both Group 1 and Group 2 did not receive prior antifungal therapy. Different BDG cutoff values were considered: 80, 200, 300, 400, and ≥500 pg/mL. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve were calculated.Results: A total of 1,296 patients were studied. Of them, 100 patients (candidemic) were in Group 1 and the remaining 1,196 patients (controls) were in Group 2. There were no differences in demographic characteristics between patients of the two groups. According to the above cutoff values, sensitivity (%) and specificity (%) of the BDG assay ranged from 91 to 60.7 and 87.7 to 97.8, respectively, whereas the PPV (%) and NPV (%) ranged from 38.2 to 68.3 and 99.1 to 97.0, respectively.Conclusion: Serum BDG has a very high NPV in a population witĥ10% prevalence of candidemia. This NPV may support decisions to discontinue antifungal therapy in those patients who were empirically treated because of the suspect of candidemia.

AB - Objectives: To assess the performance of the (1,3)-β-D-glucan (BDG) detection assay in a large cohort of patients with suspected candidemia who were admitted to non-intensive care unit hospital wards.Methods: This observational, retrospective cohort study was conducted in a 1,100-bed university hospital in Rome, where an infectious disease consultation team has been operational. Two groups of patients were included in the analysis: Group 1, patients with Candida bloodstream infection (BSI) who had at least one BDG test performed ±48 hours from the first positive blood culture (Candida BSI Group) and Group 2, patients with risk factors for candidemia who had at least one BDG test but had negative blood cultures (Control Group). Both Group 1 and Group 2 did not receive prior antifungal therapy. Different BDG cutoff values were considered: 80, 200, 300, 400, and ≥500 pg/mL. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve were calculated.Results: A total of 1,296 patients were studied. Of them, 100 patients (candidemic) were in Group 1 and the remaining 1,196 patients (controls) were in Group 2. There were no differences in demographic characteristics between patients of the two groups. According to the above cutoff values, sensitivity (%) and specificity (%) of the BDG assay ranged from 91 to 60.7 and 87.7 to 97.8, respectively, whereas the PPV (%) and NPV (%) ranged from 38.2 to 68.3 and 99.1 to 97.0, respectively.Conclusion: Serum BDG has a very high NPV in a population witĥ10% prevalence of candidemia. This NPV may support decisions to discontinue antifungal therapy in those patients who were empirically treated because of the suspect of candidemia.

U2 - 10.2147/IDR.S181489

DO - 10.2147/IDR.S181489

M3 - Article

VL - 12

SP - 19

EP - 24

JO - Infection and Drug Resistance

JF - Infection and Drug Resistance

SN - 1178-6973

ER -